ARTICLE | Company News
Millennium, Xoma inflammation deal
November 26, 2001 8:00 AM UTC
The companies will develop MLNM's CAB-2 and LDP-01 for certain vascular inflammation indications. XOMA will be responsible for development through the completion of Phase II testing, and MLNM will be ...